IFFGD Seeks Participants for New Focus Group on Inequalities and Disparities in Healthcare, June 2021

The following focus group is a new opportunity being established by the International Foundation for Gastrointestinal Disorders (IFFGD), a 30 year old U.S. not for profit organization focused on various gastrointestinal disorders, including IBS and other disorders of brain-gut interaction/functional gastrointestinal disorders. Below is the text of the announcement exactly as received from IFFGD. IBS

April is IBS Awareness Month 2021

April is IBS Awareness Month in many countries. During this month every year, increased and very needed attention is given to IBS and the experiences of those of us who live with it. Join IBS Impact, other affected people, families, friends, IBS and functional GI/disorder of gut-brain interaction professionals and organizations who are uniting in

American College of Gastroenterology Publishes 2020 Clinical Guidelines for IBS Management-December 2020

The American Journal of Gastroenterology has published the American College of Gastroenterology’s¬† newly updated guidelines for the management of irritable bowel syndrome (IBS) in its December 2020 issue. Seven named authors from the fields of gastroenterology¬† and gastrointestinal health psychology, represent five United States universities or academic medical centers that are leaders in IBS research.

IFFGD 2020 IBS Patients’ Illness Experience and Unmet Needs Online Survey Open For Response

Beginning in 2007, the International Foundation for Gastrointestinal Disorders (IFFGD) began conducting a multi-year comprehensive survey of people with IBS, their experiences and unmet needs. This survey attracted a large number of responses internationally and its insights have been important contributions to IBS research, medical care and support systems since then. Now in 2020, IFFGD

U.S. FDA Approves Tenapanor (Ibsrela) for Adults with IBS-C, September 2019

This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the

New Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of IBS– April 2019.

The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology,  health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University

International Foundation for Functional Gastrointestinal Disorders (IFFGD) Seeking Volunteers for New Patient Panel

The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is an established, reputable U.S. based 501c3 not-for-profit organization/charity focused on irritable bowel syndrome (IBS) and related functional gastrointestinal disorders, also known as disorders of gut-brain interaction. IFFGD was founded in 1991 by an FGID-affected family and continues to have people with FGIDs or family members/supporters among